<DOC>
	<DOCNO>NCT01754623</DOCNO>
	<brief_summary>The purpose study find program intensive chemotherapy gemcitabine , docetaxel capecitabine follow advanced form focus radiation aim participant 's tumor follow chemotherapy increase chance participant 's pancreatic tumor remove completely .</brief_summary>
	<brief_title>GTX-RT Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description>Investigators plan conduct prospective pilot phase II trial GTX-SBRT neoadjuvant treatment borderline resectable pancreatic cancer . After informed consent , pretreatment pancreatic tumor tissue collect immediately frozen time stag endoscopic ultrasound ( EUS ) . Ribonucleic acid ( RNA ) extract tumor specimen run microarray analysis determine radiosensitivity index score . Borderline resectable ( BR ) patient treat 3 cycle GTX chemotherapy follow SBRT . They restaged evaluate resectability 3 4 week later . Non-metastatic patient deem resectable neoadjuvant therapy take surgery .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must histologically cytologically confirm pancreatic adenocarcinoma borderline resectable disease . Borderline resectable lesion define : circumferential tumor abutment superior mesenteric vein ( SMV ) portal vein ( PV ) SMV/PV confluence &lt; /= 180° circumferential tumor abutment superior mesenteric artery ( SMA ) &lt; /= 180° Short segment encasement ( 360° ) PV SMV amenable partial vein resection reconstruction encasement gastroduodenal artery origin hepatic artery Patients must measurable disease No previous chemotherapy radiation pancreas Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) Patients must normal organ marrow function define : leukocyte &gt; /= 3,000/μL absolute neutrophil count &gt; /= 1,000/ μL platelet &gt; /= 100,000/ μL creatinine within normal institutional limit ( ULN ) total bilirubin allow 2x upper limit institution . Patients may biliary stent drain low total bilirubin range . Has negative serum urine pregnancy test within 7 day prior initiation therapy ( female patient childbearing potential ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Patients agree continue contraception 30 day date last study drug administration . Ability understand willingness sign write informed consent document Patients metastatic disease ineligible . Patients prior chemotherapy pancreatic adenocarcinoma Patients receive prior radiation abdominal site eligible . Patients peripheral neuropathy &gt; /= grade 2 Patients history severe hypersensitivity reaction Taxotere ( docetaxel ) , drug formulate polysorbate 80 , gemcitabine , capecitabine Patients may receive investigational agent . ECOG Performance Status 34 Pregnant breastfeed woman exclude study gemcitabine , capecitabine , docetaxel Class D agents potential teratogenic abortifacient effect . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patients must comorbid inflammatory condition bowel Crohn 's Disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Stereotactic</keyword>
	<keyword>Radiosurgery</keyword>
	<keyword>Borderline</keyword>
	<keyword>Resectable</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>SBRT</keyword>
	<keyword>GTX Chemotherapy</keyword>
</DOC>